Fluorouracil API at 50 mg/mL injectable concentration is dissolved in Water for Injection within a 316L stainless steel jacketed vessel equipped with a pH monitoring loop and a low-shear agitator. The aqueous solubility of the un-ionized substance is limited, and the compendial pH range of 8.6–9.4 is therefore a condition for maintaining the API in solution at labelled concentration; below 8.6 precipitation can occur during cooling or after carbon dioxide ingress from ambient air, while above 9.4 hydrolytic ring-opening degradation accelerates and generates measurable impurity peaks when assayed under a monograph-defined liquid chromatography method. Sodium hydroxide solution is metered into the batch under continuous pH monitoring, and the temperature is maintained below a validated set point because the aqueous degradation rate constant increases with temperature under alkaline conditions. The closed vessel is shielded from light, and the headspace may be inerted with nitrogen where the formulation permits to limit oxidative discoloration. Terminal filtration is carried out through a sterilizing-grade membrane, after which the solution is filled into amber Type I glass vials or non-PVC infusion containers depending on the downstream market. A hold-time study is required after final pH adjustment; the acceptance criterion for any individual unknown degradation product must remain within the ICH Q3B reporting threshold unless a tighter limit is set by the approved regulatory file. In-line particle counting per USP <788> and visible inspection per USP <790> are applied to release the sterile solution, and the filter housing is flushed with the drug solution to displace air before aseptic filling because residual air ingress can generate micro-bubble-related fill weight variability.

Why Does Filter Compatibility Testing Require a Microbial Retention Challenge in Parallel with Extractables Profiling?

In aseptic processing of fluorouracil injection, the compatibility of a sterilizing-grade filter cannot be reduced to a bacterial retention test alone because the low-molecular-weight polar pyrimidine analogue interacts with membrane polymers through mechanisms that are not detected by a simple pore-size retention challenge. Any change in filter supplier, membrane polymer, or prefilter configuration triggers a revalidation exercise under USP <1229> and ASTM F838-20, because the drug solution at pH 8.6 to 9.4 may leach membrane wetting agents or introduce sub-visible particles that are not captured by routine HPLC assay alone. The validation package comprises three parallel streams: first, a bacterial retention challenge with Brevundimonas diminuta at a challenge concentration of not less than 10⁷ CFU/cm² effective filtration area; second, an extractables screen conducted in a simulated process fluid at the upper temperature of the filtration loop and for twice the production hold time, with the resulting extractables identified by GC-MS and LC-QTOF and reported against the ICH Q3C residual solvent framework where applicable; and third, a leachables study on the filter sterilising train under worst-case batch cycling to confirm that no extractable species exceeds a toxicological threshold derived from the permitted daily exposure. Production-scale filtration cartridges are commonly of polyethersulfone or PVDF membrane construction in 10-inch or 30-inch formats, and the pressure differential across the membrane is monitored with a validated pressure transducer; a rise across the membrane during a campaign may indicate pH-shift precipitation of the API or excipient salt, not merely membrane plugging. For this reason the filtration line is equipped with an in-line turbidity sensor downstream of each filter housing, and the acceptance criterion for sub-visible particulate matter per USP <788> Method 1 Light Obscuration for large-volume parenterals is 25 particles per mL at 10 µm and 3 particles per mL at 25 µm, while small-volume parenterals are controlled at 6000 particles per container at 10 µm and 600 particles per container at 25 µm. The simultaneous execution of microbial retention and extractables profiling avoids the false conclusion that a filter which retains bacteria is automatically suitable for a high-pH fluorouracil solution, because the compatibility endpoint is chemical inertness, not merely pore-size retention.

When a 5-FU Tablet Is Compressed Despite Saturable First-Pass Metabolism

Because the presystemic clearance of fluorouracil is dominated by dihydropyrimidine dehydrogenase in the intestinal mucosa and liver, the development pathway for an oral fluorouracil tablet or capsule is not a direct substitution of the injectable formulation into a standard direct-compression matrix. The processing window for a fluorouracil tablet begins with the selection of a non-alkaline filler such as microcrystalline cellulose, anhydrous dibasic calcium phosphate, or pregelatinized starch, because the API exhibits pH-dependent solubility and alkaline microenvironments from magnesium oxide or sodium carbonate excipients can generate localised degradation even when the bulk blend shows acceptable assay. Tablet compression is typically operated on a rotary tablet press with a compression force range validated against disintegration time and dissolution profile; however, published data for an officially approved fluorouracil oral tablet monograph is limited, and development protocols fall under the general requirements of ICH Q6A, USP <711> dissolution, and USP <905> uniformity of dosage units rather than a specific compendial monograph. If a modified-release tablet is intended to blunt the peak plasma concentration, the polymer matrix must be evaluated for hydration-induced pH shifts, because a matrix that swells and retains water may create a diffusion boundary layer with a local pH different from the bulk intestinal fluid and alter the release of the API. Tablet hardness and friability are not merely mechanical parameters; over-lubrication with magnesium stearate can form a hydrophobic film on the API particles, delay dissolution, and complicate the in vitro-in vivo correlation, so the lubricant level is usually kept at or below 1.0% w/w when a disintegration-limited formulation is being developed. Process analytical technology may include near-infrared blend uniformity monitoring on the press feed frame, but the NIR model must be challenged with drug substance lots spanning the specified particle size distribution because fluorouracil crystals can exhibit batch-to-batch variation in crystal habit and specific surface area. Granulation for oral tablets or capsules is generally dry granulation rather than aqueous wet granulation; this point is expanded in the following scenario.

Across capsule and granule manufacturing lines, dry granulation by roller compaction is the preferred size-enlargement route when fluorouracil is formulated into granules for capsule filling or tablet compression, because the aqueous binder addition used in conventional wet granulation would expose the API to a moisture peak that can hydrolyse the pyrimidine ring under heat and alkaline pH. The granulation train is typically configured with a roller compactor operating at a roll force that is deliberately set at the lower end of the design range to limit the formation of fines, because fluorouracil granules that are overcompacted can develop a hard shell that resists disintegration in acidic media despite having acceptable flowability. The feed system is fitted with a vertical screw feeder and a vacuum deaeration line to remove entrained air from the precompacted powder, and the mill screen aperture is selected to shift the granule size distribution toward a D50 of 150 µm to 250 µm rather than a broader distribution that would compromise capsule weight uniformity. Released granules are tested for moisture content by Karl Fischer titration with an acceptance criterion often tightened to NMT 1.0% w/w in development studies of hydrolysis-sensitive APIs; published data for fluorouracil-specific granule degradation kinetics in this configuration is limited, so conservative moisture limits are derived from pharmaceutical development stability studies. Capsule filling is conducted on a dosator or tamping-pin machine, and the fill weight is monitored by in-process weight checks at intervals defined in the batch record. The low-dose capsule configuration requires a pre-blend of the API with a diluent to avoid segregation, and the final blend is sampled at multiple drum locations before encapsulation to verify homogeneity. For hard gelatin capsule shells, shell moisture transfer into the granule matrix is evaluated under 25°C and 60% RH conditions, because gelatin is hygroscopic and moisture migration above the specified limit can introduce a dissolution failure or a colour-change reaction with the API. The capsule process is completed with a metal detector and a weight sorter, and the acceptance limits for content uniformity follow USP <905>; if the blend is not uniform, the corrective action is not simply extended blending time but reduction of the API particle size or introduction of an intermediate sieving step.

Hospital Pharmacy Dilution, Y-Site Compatibility, and Light Protection

In hospital pharmacy compounding and administration, preparation of patient-specific infusions from fluorouracil injection must be treated as a hazardous drug operation under USP <800> and the NIOSH Alert 2004-165, which requires biological safety cabinet containment, closed-system transfer devices where available, and surface deactivation with a validated cleaning sequence. The injection concentrate is transferred into 0.9% sodium chloride or 5% dextrose infusion bags; the final concentration is commonly in the range of 1 mg/mL to 50 mg/mL depending on the infusion protocol, and the admixture is visually inspected against a black-and-white background for cloudiness or precipitation before dispensing. Although fluorouracil is more soluble at alkaline pH, the dilution factor in an infusion bag is generally sufficient to maintain solubility after pH dilution, but the final admixture should be protected from light and used within a facility-validated beyond-use date because photodegradation can generate discoloration products that are not captured by a simple pH check. Y-site compatibility with other antineoplastic agents is evaluated by reference to published compatibility studies; fluorouracil should not be assumed compatible with all agents simply because it is a small molecule, and the absence of visible haze at the Y-site is not sufficient evidence of chemical stability. The pharmacy production line may use an automated compounding device with gravimetric verification to ±5% of the target weight, and the device tubing is primed with the drug solution only after the software verifies the density and viscosity input because fluorouracil injection has a viscosity slightly above water. The final container is labelled with the hazardous drug symbol and stored under light-protected and temperature-controlled conditions until administration. The administration set is non-PVC and non-DEHP when the institutional hazardous drug risk assessment or drug-specific compatibility data indicates a need to avoid plasticiser extraction from PVC tubing, and the pump cassette is calibrated for the specific tubing lot to avoid underdosing at low flow rates. Extravasation of fluorouracil is managed by the institution-specific cytotoxic extravasation protocol, and the infusion site is monitored continuously because tissue exposure to the antimetabolite can produce localised irritation even when the infusion is otherwise uneventful.

Ampoules, Vials, and Pre-Filled Syringes Represent Distinct Container-Closure Risk Profiles for Fluorouracil Injection

For fluorouracil injection, the choice of amber Type I glass vials, ampoules, or polymer pre-filled syringes is not governed by cosmetic preference but by the interaction of the pH 8.6 to 9.4 drug solution with the container surface and the headspace gas over the shelf life. Type I borosilicate glass offers low extractable risk, but the alkaline pH can accelerate glass delamination in the form of lamellae or flakes if the glass surface has not been pre-treated and the terminal sterilisation cycle is pushed to excessive time-temperature conditions; delamination failure is detected by USP <1660> and visible inspection rather than by HPLC alone. Ampoules introduce an additional risk of glass particle contamination at break opening, so a snap-open design with a colour-break ring and a filtered withdrawal needle is used, and the fill volume is validated for the viscosity and surface tension of the drug solution to prevent meniscus variation that would affect the dose pulled into a syringe. Pre-filled syringes require compatibility tests on the silicone oil lubricant, the rubber stopper, and the tip cap because fluorouracil at alkaline pH can interact with residual monomers or curing agents in bromobutyl elastomer, generating extractables that are not seen in glass ampoules. The syringe barrel is oxygen-permeable if polymer-based, so the package configuration may include a secondary oxygen barrier film or inert gas flushing to maintain solution colour over the labelled shelf life. Terminal sterilisation of the filled container, when applicable, is usually performed by steam sterilisation at 121°C for a validated cycle, but the thermal exposure must be balanced against degradation; published data for fluorouracil terminal sterilisation cycles is limited, so many filings rely on aseptic filtration followed by aseptic filling under ISO 14644-1 Class 5 conditions. Container-closure integrity is tested by dye ingress or vacuum decay per USP <1207>, and the acceptance criterion is no measurable leak in a defect-packaged control set. The batch release strategy therefore includes not only assay, related substances, and sterility but also container-closure integrity, visible and sub-visible particulate counts, pH, and osmolality where the label specifies a compounded or ready-to-administer presentation.